Dihexa

Mechanism

Acts as a hepatocyte growth factor mimetic, potentiating c-Met receptor activation and promoting dendritic arborisation and synaptogenesis.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Cognitive impairment research
• Synaptogenesis research
• Preclinical neuroprotection context

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet; MedChemExpress gives DMSO stock -80C 6 months / -20C 1 month (https://www.medchemexpress.com/Dihexa.html). Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — S0 catch-all. the list Not named; investigational HGF/c-Met modulator with no approval. Also arguably S2.3, which names hepatocyte growth factor (HGF) and growth factor modulators.

Literature on file 2

• animal in vivo
  AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (Brain Sciences 2021, cited 15x) graded on: an animal model — “Mouse”
• animal in vivo
  Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies (Annals of Medicine and Surgery 2021, cited 1x) graded on: an animal model — “rat”

What is circulated not evidence 6

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose common nothing on file either way

  5 to 20 mg once daily, orally or sublingually, is the dose reported across nootropic communities, with some sources going to 20-30 mg and a few to 45 mg.

  most commonly 5-20 mg per day, once daily, with some references reaching 20-30 mg

  On the record The record holds no dosing at all for dihexa. There is no dose, no range, no unit and no cycle on file, while a fully specified milligram protocol circulates freely. This is the widest gap in this slice.

  Source 1 · Source 2

• unverified community data sourcing occasional agrees with the record

  The circulated figures are traced by at least one guide to vendor copy and LongeCity forum threads rather than to any pharmacokinetic study, and the only controlled data is oral gavage at roughly 1.25-2 mg/kg in rodents.

  vendor copy and forum threads such as LongeCity, not from pharmacokinetic data.

  On the record The record grades dihexa at the animal rung, on an animal model, and holds no half-life. It agrees the evidence is animal, and holds no dose to compare the rodent figure against.

  Source 1

• unverified community data dose common nothing on file either way

  A transdermal route using a DMSO carrier is widely described, alongside oral and injectable forms.

  no human pharmacokinetic data to settle which, if any, delivers the compound effectively

  On the record The record lists oral, sublingual and subcutaneous as routes. The transdermal-DMSO route in wide community use is not among them, and no bioavailability figure is on file for any of the three that are.

  Source 1

• unverified community data side effect common nothing on file either way

  Community side-effect reports include headache, brain fog, irritability, anxiety, nausea, appetite and sleep changes, blood-pressure changes, and skin reactions from the DMSO carrier.

  headache, brain fog or mental fatigue, irritability, anxiety, nausea or other GI upset, appetite and sleep changes, blood-pressure changes, and skin reactions with transdermal-DMSO use

  On the record The record holds no side effects at all for dihexa. Nine distinct reported effects circulate against a record that holds none.

  Source 1

• unverified community data side effect occasional nothing on file either way

  A theoretical cancer concern is raised in some guides on the grounds that the HGF/c-Met pathway dihexa acts on is dysregulated in some cancers, and is explicitly framed as mechanistic reasoning rather than an observed effect.

  theoretical oncological concern

  On the record Not on file. The record holds no side effects, no contraindication and no mechanistic risk note for dihexa. The community is carrying a caution the record does not.

  Source 1

• unverified community data titration common nothing on file either way

  Cycling of four to eight weeks on and four weeks off is described as standard.

  Cycling on and off is commonly described, with no human safety data behind any duration.

  On the record Not on file. The record holds no cycle length for dihexa because it holds no dosing at all.

  Source 1 · Source 2

Identity

PubChem CID 129010512 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 129010512, the identifier on this record.

Molecular weight

504.7

Molecular formula

C27H44N4O5

CAS number

1401708-83-5

PubChem CID

129010512

InChI key

XEUVNVNAVKZSPT-JTJYXVOQSA-N

Sequence

YI

SMILES

CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N

InChI

InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1

Listed prices 54

What 37 shops we track listed for Dihexa, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record